Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes

Mirataollah Salabati; Charles Huang; Alireza Kamalipour; Hannah J. Yu; Raziyeh Mahmoudzadeh; Karen Jeng-Miller; Eric Chen; Chirag P. Shah; Charles C. Wykoff; Jason Hsu

doi:10.1016/j.xops.2023.100372

Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes

Mirataollah Salabati, Charles Huang, Alireza Kamalipour, Hannah J. Yu, Raziyeh Mahmoudzadeh, Karen Jeng-Miller, Eric Chen, Chirag P. Shah, Charles C. Wykoff, Jason Hsu

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

PURPOSE: To compare visual acuity (VA) changes using standardized ETDRS best-corrected visual acuity (BCVA) and nonstandardized Snellen VA among subjects enrolled in clinical trials.

DESIGN: Retrospective study.

PARTICIPANTS: Patients enrolled in prospective clinical trials at 3 urban retina practices.

METHODS: Best available Snellen VA at the clinic visit before study entry and after exit were compared with the ETDRS BCVA at trial entry and exit. The correlation and discrepancies between Snellen VA and ETDRS methods as well as the VA changes from trial entry to exit were evaluated.

MAIN OUTCOME MEASURES: The discrepancy between VA change from trial entry to exit using Snellen VA versus ETDRS BCVA methods.

RESULTS: A total of 273 eyes were included. The mean (standard deviation [SD]) Snellen VA was 58.1 (20) ETDRS-equivalent letters (Snellen 20/69) at the clinic visit before trial entry and 61.6 (21) ETDRS-equivalent letters (Snellen 20/59) at the visit after trial exit. The mean (SD) ETDRS BCVA was 65.5 (16) letters (Snellen 20/49) at trial entry and 70.5 (17) letters (Snellen 20/39) at trial exit. The mean VA change from trial entry to exit was not significantly different for ETDRS (5 letters of vision gain) compared with Snellen (3.6 letters of vision gain) methods ( P = 0.061). Eyes with baseline Snellen VA 20/50 or worse gained significantly more letters using Snellen (9.3 ± 22.3 letters) compared with ETDRS (5.2 ± 18.7 letters; P = 0.012). Among eyes with baseline Snellen VA of > 20/50, VA gain was significantly greater with the ETDRS method (4.9 ± 12.3 letters) compared with Snellen (-1.5 ± 12.3 letters; P < 0.001).

CONCLUSIONS: The mean VA change from clinical trial entry to exit was similar between the ETDRS and Snellen methods. However, among patients with worse baseline Snellen vision, the magnitude of VA change was greater with Snellen compared with ETDRS, whereas among those with better baseline vision, this magnitude was greater with the ETDRS method. Understanding the proportion of the study population with varying VA levels may have implications for interpreting VA outcomes from retrospective clinic-based studies compared with those reported in clinical trials.

FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.

Original language	English (US)
Article number	100372
Pages (from-to)	100372
Journal	Ophthalmology Science
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.xops.2023.100372
State	Published - Mar 1 2024

Keywords

Clinical trial
ETDRS
Snellen
Visual acuity change

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.xops.2023.100372

Cite this

@article{179d90a548fe424c9f338dd061d459c6,

title = "Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes",

abstract = "PURPOSE: To compare visual acuity (VA) changes using standardized ETDRS best-corrected visual acuity (BCVA) and nonstandardized Snellen VA among subjects enrolled in clinical trials.DESIGN: Retrospective study.PARTICIPANTS: Patients enrolled in prospective clinical trials at 3 urban retina practices.METHODS: Best available Snellen VA at the clinic visit before study entry and after exit were compared with the ETDRS BCVA at trial entry and exit. The correlation and discrepancies between Snellen VA and ETDRS methods as well as the VA changes from trial entry to exit were evaluated.MAIN OUTCOME MEASURES: The discrepancy between VA change from trial entry to exit using Snellen VA versus ETDRS BCVA methods.RESULTS: A total of 273 eyes were included. The mean (standard deviation [SD]) Snellen VA was 58.1 (20) ETDRS-equivalent letters (Snellen 20/69) at the clinic visit before trial entry and 61.6 (21) ETDRS-equivalent letters (Snellen 20/59) at the visit after trial exit. The mean (SD) ETDRS BCVA was 65.5 (16) letters (Snellen 20/49) at trial entry and 70.5 (17) letters (Snellen 20/39) at trial exit. The mean VA change from trial entry to exit was not significantly different for ETDRS (5 letters of vision gain) compared with Snellen (3.6 letters of vision gain) methods ( P = 0.061). Eyes with baseline Snellen VA 20/50 or worse gained significantly more letters using Snellen (9.3 ± 22.3 letters) compared with ETDRS (5.2 ± 18.7 letters; P = 0.012). Among eyes with baseline Snellen VA of > 20/50, VA gain was significantly greater with the ETDRS method (4.9 ± 12.3 letters) compared with Snellen (-1.5 ± 12.3 letters; P < 0.001). CONCLUSIONS: The mean VA change from clinical trial entry to exit was similar between the ETDRS and Snellen methods. However, among patients with worse baseline Snellen vision, the magnitude of VA change was greater with Snellen compared with ETDRS, whereas among those with better baseline vision, this magnitude was greater with the ETDRS method. Understanding the proportion of the study population with varying VA levels may have implications for interpreting VA outcomes from retrospective clinic-based studies compared with those reported in clinical trials.FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.",

keywords = "Clinical trial, ETDRS, Snellen, Visual acuity change",

author = "Mirataollah Salabati and Charles Huang and Alireza Kamalipour and Yu, {Hannah J.} and Raziyeh Mahmoudzadeh and Karen Jeng-Miller and Eric Chen and Shah, {Chirag P.} and Wykoff, {Charles C.} and Jason Hsu",

note = "Publisher Copyright: {\textcopyright} 2023 American Academy of Ophthalmology",

year = "2024",

month = mar,

day = "1",

doi = "10.1016/j.xops.2023.100372",

language = "English (US)",

volume = "4",

pages = "100372",

journal = "Ophthalmology Science",

issn = "2666-9145",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials

T2 - Implications for Clinic-Based Outcomes

AU - Salabati, Mirataollah

AU - Huang, Charles

AU - Kamalipour, Alireza

AU - Yu, Hannah J.

AU - Mahmoudzadeh, Raziyeh

AU - Jeng-Miller, Karen

AU - Chen, Eric

AU - Shah, Chirag P.

AU - Wykoff, Charles C.

AU - Hsu, Jason

PY - 2024/3/1

Y1 - 2024/3/1

N2 - PURPOSE: To compare visual acuity (VA) changes using standardized ETDRS best-corrected visual acuity (BCVA) and nonstandardized Snellen VA among subjects enrolled in clinical trials.DESIGN: Retrospective study.PARTICIPANTS: Patients enrolled in prospective clinical trials at 3 urban retina practices.METHODS: Best available Snellen VA at the clinic visit before study entry and after exit were compared with the ETDRS BCVA at trial entry and exit. The correlation and discrepancies between Snellen VA and ETDRS methods as well as the VA changes from trial entry to exit were evaluated.MAIN OUTCOME MEASURES: The discrepancy between VA change from trial entry to exit using Snellen VA versus ETDRS BCVA methods.RESULTS: A total of 273 eyes were included. The mean (standard deviation [SD]) Snellen VA was 58.1 (20) ETDRS-equivalent letters (Snellen 20/69) at the clinic visit before trial entry and 61.6 (21) ETDRS-equivalent letters (Snellen 20/59) at the visit after trial exit. The mean (SD) ETDRS BCVA was 65.5 (16) letters (Snellen 20/49) at trial entry and 70.5 (17) letters (Snellen 20/39) at trial exit. The mean VA change from trial entry to exit was not significantly different for ETDRS (5 letters of vision gain) compared with Snellen (3.6 letters of vision gain) methods ( P = 0.061). Eyes with baseline Snellen VA 20/50 or worse gained significantly more letters using Snellen (9.3 ± 22.3 letters) compared with ETDRS (5.2 ± 18.7 letters; P = 0.012). Among eyes with baseline Snellen VA of > 20/50, VA gain was significantly greater with the ETDRS method (4.9 ± 12.3 letters) compared with Snellen (-1.5 ± 12.3 letters; P < 0.001). CONCLUSIONS: The mean VA change from clinical trial entry to exit was similar between the ETDRS and Snellen methods. However, among patients with worse baseline Snellen vision, the magnitude of VA change was greater with Snellen compared with ETDRS, whereas among those with better baseline vision, this magnitude was greater with the ETDRS method. Understanding the proportion of the study population with varying VA levels may have implications for interpreting VA outcomes from retrospective clinic-based studies compared with those reported in clinical trials.FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.

AB - PURPOSE: To compare visual acuity (VA) changes using standardized ETDRS best-corrected visual acuity (BCVA) and nonstandardized Snellen VA among subjects enrolled in clinical trials.DESIGN: Retrospective study.PARTICIPANTS: Patients enrolled in prospective clinical trials at 3 urban retina practices.METHODS: Best available Snellen VA at the clinic visit before study entry and after exit were compared with the ETDRS BCVA at trial entry and exit. The correlation and discrepancies between Snellen VA and ETDRS methods as well as the VA changes from trial entry to exit were evaluated.MAIN OUTCOME MEASURES: The discrepancy between VA change from trial entry to exit using Snellen VA versus ETDRS BCVA methods.RESULTS: A total of 273 eyes were included. The mean (standard deviation [SD]) Snellen VA was 58.1 (20) ETDRS-equivalent letters (Snellen 20/69) at the clinic visit before trial entry and 61.6 (21) ETDRS-equivalent letters (Snellen 20/59) at the visit after trial exit. The mean (SD) ETDRS BCVA was 65.5 (16) letters (Snellen 20/49) at trial entry and 70.5 (17) letters (Snellen 20/39) at trial exit. The mean VA change from trial entry to exit was not significantly different for ETDRS (5 letters of vision gain) compared with Snellen (3.6 letters of vision gain) methods ( P = 0.061). Eyes with baseline Snellen VA 20/50 or worse gained significantly more letters using Snellen (9.3 ± 22.3 letters) compared with ETDRS (5.2 ± 18.7 letters; P = 0.012). Among eyes with baseline Snellen VA of > 20/50, VA gain was significantly greater with the ETDRS method (4.9 ± 12.3 letters) compared with Snellen (-1.5 ± 12.3 letters; P < 0.001). CONCLUSIONS: The mean VA change from clinical trial entry to exit was similar between the ETDRS and Snellen methods. However, among patients with worse baseline Snellen vision, the magnitude of VA change was greater with Snellen compared with ETDRS, whereas among those with better baseline vision, this magnitude was greater with the ETDRS method. Understanding the proportion of the study population with varying VA levels may have implications for interpreting VA outcomes from retrospective clinic-based studies compared with those reported in clinical trials.FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.

KW - Clinical trial

KW - ETDRS

KW - Snellen

KW - Visual acuity change

UR - http://www.scopus.com/inward/record.url?scp=85174043575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85174043575&partnerID=8YFLogxK

U2 - 10.1016/j.xops.2023.100372

DO - 10.1016/j.xops.2023.100372

M3 - Article

C2 - 37868803

AN - SCOPUS:85174043575

SN - 2666-9145

VL - 4

SP - 100372

JO - Ophthalmology Science

JF - Ophthalmology Science

IS - 2

M1 - 100372

ER -

Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this